Pharmacoeconomics 2008; 26 (8): 661-677
نویسندگان
چکیده
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661 1. Discrete Choice Experiments (DCEs) and Economic Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 663 2. Theoretical Basis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 664 3. Undertaking a DCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 665 3.1 Designing an Experiment to Generate Choice Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 665 3.1.1 Conceptualizing the Choice Process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 665 3.1.2 Defining Attributes and Levels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 665 3.1.3 Creating Experimental Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 667 3.1.4 Pilot Tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669 3.1.5 Sample . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670 3.1.6 Data Collection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670 3.2 Discrete Choice Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670 3.2.1 Coding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670 3.2.2 Forms of Choice Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671 3.2.3 Validity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671 3.3 Interpretation, Derivation of Welfare Measures and Other Policy Analysis . . . . . . . . . . . . . . . . . . 672 3.3.1 Predicted Probability Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672 3.3.2 Marginal Rates of Substitution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672 3.3.3 Welfare Measures to Value Health and Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672 4. The Research Frontier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 673 5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 675 Discrete choice experiments (DCEs) are regularly used in health economics to Abstract elicit preferences for healthcare products and programmes. There is growing recognition that DCEs can provide more than information on preferences and, in particular, they have the potential to contribute more directly to outcome measurement for use in economic evaluation. Almost uniquely, DCEs could potentially contribute to outcome measurement for use in both cost-benefit and cost-utility
منابع مشابه
Pharmacoeconomics 2008; 26 (1): 75-90
Background: Invasive fungal infections in neutropenic patients treated for
متن کاملPharmacoeconomics 2007; 25 (8): 649-664
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649 1. Frequentist and Bayesian Paradigms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650 1.1 Contrasts: Parameter Estimates, Confidence Intervals, Hypothesis Testin...
متن کاملThe Fontaine-mazur Conjecture for Gl2
Introduction 641 1. Breuil-Mézard conjecture and the p-adic local Langlands 644 (1.1) The Breuil-Mézard conjecture 644 (1.2) Review of Colmez’s functor 647 (1.3) Hilbert-Samuel multiplicities 650 (1.4) Representations and pseudo-representations 653 (1.5) GL2(Qp)-representations mod p. 657 (1.6) Local patching and multiplicities 661 (1.7) From pseudo-representations to representations 669 2. Mod...
متن کاملThe Impact of Adherence and Development of Neutralizing Antibodies to Interferons β on Treatment of Multiple Sclerosis in the Czech Republic.
1 Steinberg SC et al., Clin Drug Investig. 2010;30(2):89-100 • 2 Clerico M et al. Neurol Sci. 2007 Aug 15;259(1-2):104-8 • 3 Sorensen PS et al. Mult Scler. 2008 Jul;14(6):837-42 • 4 Koch-Henriksen N et al. Mult Scler. 2009 May;15(5):601-5 • 5 Paolicelli D et al. J Neurol. 2013 Jun;260(6):1562-8 • 6 Farrell R et al. Mult Scler. 2008 Mar;14(2):212-8 • 7 Devonshire V et al., Eur J Neurol. 2011 Jan...
متن کاملPharmacoeconomics 2008; 26 (9): 733-744
1 Academic Unit of Health Economics and NICE Decision Support Unit, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK 2 Centre for Health Economics, Department of Economics and NICE Decision Support Unit, University of York, Heslington, York, UK 3 Centre for Health Economics, Department of Economics, University of York, Heslington, York, UK 4 Department of Health Policy Managem...
متن کامل